Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalMarket Capitalization

RedHill Biopharma (RDHL) EBITDA Margin: 2009-2024

Historic EBITDA Margin for RedHill Biopharma (RDHL) over the last 16 years, with Dec 2024 value amounting to -174.38%.

  • RedHill Biopharma's EBITDA Margin rose 592476.00% to 5,637.14% in Q2 2023 from the same period last year, while for Jun 2023 it was -148.01%, marking a year-over-year increase of 9419.00%. This contributed to the annual value of -174.38% for FY2024, which is 54062.00% down from last year.
  • As of FY2024, RedHill Biopharma's EBITDA Margin stood at -174.38%, which was down 147.61% from 366.25% recorded in FY2023.
  • In the past 5 years, RedHill Biopharma's EBITDA Margin registered a high of 366.25% during FY2023, and its lowest value of -174.38% during FY2024.
  • Its 3-year average for EBITDA Margin is 25.30%, with a median of -115.97% in 2022.
  • In the last 5 years, RedHill Biopharma's EBITDA Margin tumbled by 58,776bps in 2020 and then surged by 48,222bps in 2023.
  • Over the past 5 years, RedHill Biopharma's EBITDA Margin (Yearly) stood at 98.95% in 2020, then slumped by 21,293bps to -113.98% in 2021, then slumped by 199bps to -115.97% in 2022, then surged by 48,222bps to 366.25% in 2023, then tumbled by 54,062bps to -174.38% in 2024.